Clinical Hereditary Cancer Syndromes and Gene Panel TestingOctober 15th 2016
For some time, genetic testing has been predictive and prognostic. It is now assuming a therapeutic role as well. An example is the targeting of breast cancer patients with BRCA mutations for treatment with PARP inhibitors.
The Emerging Role of Checkpoint Inhibitor Therapy in Hodgkin LymphomaOctober 15th 2016
Ultimately, the management goal is not for patients with relapsed/refractory disease to live with chronic Hodgkin lymphoma while receiving immune checkpoint blockade therapy, but rather to cure more patients with first- or second-line therapy.